Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 0022

Next Previous
Drug Profile

AZD 0022

Alternative Names: AZD-0022

Latest Information Update: 18 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 29 Jan 2026 AstraZeneca terminates the phase-I/IIa ALAFOSS-01 trial in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in USA, Japan, South Korea, and Australia due to strategic company portfolio prioritization (NCT06599502)
  • 30 Sep 2025 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in South Korea, Japan, Australia, USA (PO), before September 2025, due to strategic reasons (AstraZeneca pipeline, December 2025)
  • 30 Sep 2025 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in South Korea, Japan, Australia, USA (PO), before September 2025, due to strategic reasons (AstraZeneca pipeline, December 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top